Impact of COVID- 19 Infection Among Hospitalized Amyotrophic Lateral Sclerosis Patients
- PMID: 33596004
- PMCID: PMC7892201
- DOI: 10.1097/CND.0000000000000335
Impact of COVID- 19 Infection Among Hospitalized Amyotrophic Lateral Sclerosis Patients
Conflict of interest statement
R. Govindarajan serves on the advisory board of Alexion Pharmaceuticals, Argenx Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst pharmaceuticals, Roche pharmaceuticals, Amicus pharmaceuticals, Sarepta pharmaceuticals and has received research support from Alexion Pharmaceuticals, Ra Pharmaceuticals, Strongbridge Pharmaceuticals, American Academy of Neurology, AMARC Enterprises/Poly-MVA, Dysimmune Foundation and InfuCare. He has received speaking honorarium from American Academy of Neurology, Alexion Pharmaceuticals, Mitsubishi Tanabe Pharmaceuticals, Catalyst Pharmaceuticals, Muscular Dystrophy Association and publication honorarium from Springer Publishing, USA, and royalties from CRC press. The remaining authors report no conflicts of interest.
References
-
- Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation and treatment coronavirus (COVID-19). In: Statpearls [internet]. Treasure Island, FL: StatPearls Publishing; 2020. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical